The U.S. Food and Drug Administration (FDA) has launched Phase II of its voluntary sodium reduction targets, aiming to lower average sodium intake to 2,750 milligrams per day over the next three years, a 20% decrease from pre-2021 levels. This initiative is part of a broader effort to combat diet-related chronic diseases, as excessive sodium intake is linked to high blood pressure, heart disease, and stroke. While the FDA reports that 40% of food categories have met or are close to meeting Phase I targets, the current goal still exceeds the recommended limit of 2,300 mg/day. Major food companies, including PepsiCo and Kraft Heinz, are expected to be impacted by these new guidelines, although the FDA's data on industry compliance is based on two-year-old information. The initiative is part of a larger public health strategy to reduce sodium and improve nutrition, which is seen as crucial for advancing health equity and reducing chronic disease burdens. The FDA is also seeking public feedback on these targets until November 14, 2023.